Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Mounjaro (tirzepatide) works on both GLP-1 and GIP receptors and has shown greater average weight loss in trials (around 21% on the highest dose over 72 weeks compared with 15% for Wegovy 2.4 mg, or 21% on the new Wegovy 7.2 mg dose)
Demand for Wegovy and Ozempic exploded far beyond Novo Nordisk's manufacturing capacity
neither, 2.1%)
Research Overview Retatrutide is a triple receptor agonist peptide targeting the GIP, GLP-1, and glucagon receptors
The last injection I had was January 28th
The $298 genetic test analyzes variants in GIPR and FTO, and MC4R genes that influence insulin sensitivity, appetite regulation, and metabolic response to GLP-1 therapy
US$ 22.02
US$ 24.21
US$ 29.65
US$ 21.85
US$ 28.86
US$ 24.09
US$ 25.73
US$ 23.33
US$ 20.82
